Thursday, November 12th, 2020 until
Thursday, January 14th, 2021 noon, JST
Abstract submission has been closed.
1. Presentation Style and Language
All abstracts for General Presentation must be written in English.
|Lecture form||Title||Presentation Language|
|Symposium 1||Advanced Device Management for Heart Failure Patients||
|Symposium 2||Pacing for the Reduction of AF and Heart failure||
|Symposium 3||Total Management for the Prevention of Sudden Cardiac Death||
|Symposium 4||Autonomic Nervous System, Sudden Death, and Related Diseases||
|Symposium 5||Recent Findings with the Advance of 3D Electroanatomical Mapping in Scar-related VT||
|Symposium 6||Future of catheter ablation for complex arrhythmias||
|Symposium 7||Novel Approach to Ablation for Persistent AF||
|Symposium 8||Outflow Tract PVCs: What We Know and We Don’t Know||
|Symposium 9||Autonomic Tone and Cardiac Arrhythmias: Insight Into Therapeutic Approach||
|Symposium 10||Diagnosis and management for Primary Inherited Arrhythmia and Cardiomyopathy||
|Panel Discussion||Transvenous Lead Extraction||
2. Body of the Abstract
There is a 250 word limit to the body of your abstract (Please do not include author name(s) and organizational affiliation(s)). It may include one diagram, which should be in GIF or JPEG format and of 300 KB or less in size. The diagram can be in either landscape or portrait orientation and will be reduced to about 75 mm x 45 mm when printed. Please note that even if you submit a color diagram, it will be printed in black and white. In case the abstract includes a diagram, the body of the abstract should be up to 150 words.
3. Registration ID and Password
※If you have already created your account for JHRS2020, please use (log-in) with your existing account.
Upon your abstract submission, you should “create new account” at first. With this ID and your own password you chose when you first registered as a user, you will be able to log in to your personal abstract submission page and edit or amend your abstract at any time up to the deadline of abstract submission.
※You will be responsible for safekeeping of your password and other confidential information.
4. Presentation Language for General Presentation
Please select your presentation language, among “English”, “Japanese or English” and “Japanese preferred” at the time of registration. Note that all slides and posters must be in English only.
5. Presentation Style for General Presentation
Please select your presentation style, either “oral or poster” or “poster preferred” at the time of registration.
6. Type of Presentation Language
The presentation language will, in principle, be as per your indication. The presentation style (oral or poster), however, will be determined by the congress secretariat with regard to the schedule.
7. Publication of Accepted Abstracts
Accepted abstracts, not only the body of abstract but also abstract title, author's name and organizational affiliation will be published exactly as you registered online. We recommend you to carefully read the instructions as you fill out required information.
To submit an abstract, please sing in form the “Abstract Submission” button at the bottom of this page and follow the instructions. The registration period starts from Thursday, November 12th, 2020 until Thursday, January 14th, 2021 noon, JST.
The category of your abstract is required to process your application. Please choose from the following list the number that best describes the subject of your abstract.
Please make sure that No "Case reports" is accepted.
|1||Ion Channels and Transporters: Molecular Structure, Function, and Regulation||6||Computer Modeling / Simulation|
|2||Ion Channels and Transporters: Micro Anatomy and Pathology||7||Intact Heart Electrophysiology (includes Pharmacology and Optical Mapping)|
|3||Genomics: Bench||8||Whole Animal Electrophysiology and Pharmacology (includes Neurohumoral Modulation)|
|5||Cell Physiology, Pharmacology, and Signaling|
|10||Device Technology||12||Indications and Complications|
|14||Device Technology||16||Indications and Complications|
|18||Device Technology||20||Indications and Complications|
|22||Device Technology||24||Indications and Complications|
|27||Extraction / Removal||30||Others|
|31||Monitoring & Follow-up||32||Outcomes, Quality Measures & Complications|
|33||Clinical Studies / Outcomes||37||Ablation|
|34||Experimental Methods||38||Clinical Studies|
|35||Quality Measures & Complications||39||Drug Therapy|
|36||Mapping & Imaging||40||Others|
|41||Clinical Studies / Outcomes||45||Ablation|
|42||Experimental Methods||46||Clinical Studies|
|43||Quality Measures & Complications||47||Others|
|44||Mapping & Imaging||48||Drug Therapy|
|49||Clinical Studies / Outcomes||53||Ablation|
|50||Experimental Methods||54||Clinical Studies|
|51||Quality Measures & Complications||55||Others|
|52||Mapping & Imaging||56||Drug Therapy|
|57||Risk Assessment (SAECG/TWA, HRV, QT interval etc. )||59||Prevention / Treatment|
|58||Epidemiology / Physiology||60||Others|
|61||Mechanism / Diagnosis||64||Clinical Studies|
|62||Prevention / Treatment||65||Others|
|63||Drug Therapy and Devices|
|66||Atrial fibrillation / Atrial flutter||69||Heart failure|
|67||SVT / AVNRT / WPW / AT||70||Others|
|68||VT / VF / VPC|
|72||Brugada syndrome, Early repolarization syndrome, and Idiopathic VF||73||LQT syndrome, ARVC, and others|
|84||Pediatric Cardiology||87||Training and Education|
|85||Adult Congenital Heart Disease||88||Others|
|89||Reimbursement, Regulation, and Health policy|
Please indicate whether or not you would like your abstract to be forwarded to the YIA selection process. The final nominees will be selected based on peer-review recommendation. Those finalists will make a presentation for the final selection at the YIA session during the congress.
If you have any queries about the submission process or acceptance result, please email the Congress Secretariat (E-mail: email@example.com). Please make sure to indicate your registration number in your inquiry.)